| pubmed-article:9631414 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9631414 | lifeskim:mentions | umls-concept:C0072899 | lld:lifeskim |
| pubmed-article:9631414 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:9631414 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:9631414 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:9631414 | lifeskim:mentions | umls-concept:C0671372 | lld:lifeskim |
| pubmed-article:9631414 | lifeskim:mentions | umls-concept:C0815279 | lld:lifeskim |
| pubmed-article:9631414 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:9631414 | pubmed:dateCreated | 1998-8-24 | lld:pubmed |
| pubmed-article:9631414 | pubmed:abstractText | Quinoxalinediones such as NBQX are neuroprotective in most models of cerebral ischemia but their poor solubility results in nephrotoxicity limiting their clinical utility. We have investigated the neuroprotective effects of a water soluble AMPA receptor antagonist, YM872, using two in vitro models. The viability of cortical cultures exposed to 400 microM AMPA for 15 min (16.4 +/- 2.6%; n = 10) was significantly (p < 0.05) increased (84.7 +/- 4.6%; n = 6) with YM872 (10 microM) in a concentration-dependent manner. Evoked post-synaptic response amplitudes in oxygen-glucose deprived hippocampal slices treated with 10 microM YM872 (3.5 +/- 0.3 mV; n = 27) were significantly different from untreated deprived slices (0.3 +/- 0.1 mV; n = 31, p < 0.05) and the CA1 neurons appeared viable using a confocal live/dead fluorescence assay with confocal microscopy. The neuroprotection seen with YM872 in vitro warrants further investigation in vivo. | lld:pubmed |
| pubmed-article:9631414 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9631414 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9631414 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9631414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9631414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9631414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9631414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9631414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9631414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9631414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9631414 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9631414 | pubmed:month | May | lld:pubmed |
| pubmed-article:9631414 | pubmed:issn | 0959-4965 | lld:pubmed |
| pubmed-article:9631414 | pubmed:author | pubmed-author:MurrayC LCL | lld:pubmed |
| pubmed-article:9631414 | pubmed:author | pubmed-author:MonettiNN | lld:pubmed |
| pubmed-article:9631414 | pubmed:author | pubmed-author:MorleyPP | lld:pubmed |
| pubmed-article:9631414 | pubmed:author | pubmed-author:SmallD LDL | lld:pubmed |
| pubmed-article:9631414 | pubmed:author | pubmed-author:Kawasaki-Yats... | lld:pubmed |
| pubmed-article:9631414 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9631414 | pubmed:day | 11 | lld:pubmed |
| pubmed-article:9631414 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:9631414 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9631414 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9631414 | pubmed:pagination | 1287-90 | lld:pubmed |
| pubmed-article:9631414 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:meshHeading | pubmed-meshheading:9631414-... | lld:pubmed |
| pubmed-article:9631414 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9631414 | pubmed:articleTitle | Neuroprotective effects of a novel AMPA receptor antagonist, YM872. | lld:pubmed |
| pubmed-article:9631414 | pubmed:affiliation | Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada. | lld:pubmed |
| pubmed-article:9631414 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9631414 | pubmed:publicationType | In Vitro | lld:pubmed |
